Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. - Wikidata - awgldk - TriplyDB

Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.

Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.

http://www.wikidata.org/entity/Q33973884

about

Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.Have we overestimated the benefit of human(ized) antibodies?Management of rheumatoid arthritis: Impact and risks of various therapeutic approaches Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis.Novel treatment options for ulcerative colitis.Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics Golimumab: A Novel Anti-Tumor Necrosis Factor.

P2860

Q30717002-99D431B6-E475-429B-B2B4-366114B3F13A Q34142714-7872194D-3CB7-43EA-A288-A55EEE62F6CC Q39646028-A9615026-B90E-451F-B672-1953F54CFF37 Q41457227-C72EB9FF-5685-44E5-AE10-223412E79954 Q41949151-2C286683-55EA-433C-9D74-4692EDCBC39B Q42506636-4137B6C3-3209-480B-BECC-DD707D47AD4B Q55424021-D3EC1CDE-EC5D-4DAE-9548-2980A49289CD

P2860

Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.

http://www.wikidata.org/entity/Q33973884

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Golimumab: A novel human anti- ...... itis, and psoriatic arthritis.

@ast

Golimumab: A novel human anti- ...... itis, and psoriatic arthritis.

@en

type

label

Golimumab: A novel human anti- ...... itis, and psoriatic arthritis.

@ast

Golimumab: A novel human anti- ...... itis, and psoriatic arthritis.

@en

prefLabel

Golimumab: A novel human anti- ...... itis, and psoriatic arthritis.

@ast

Golimumab: A novel human anti- ...... itis, and psoriatic arthritis.

@en

P1433

Q33973884-9D9270C8-84E1-40CF-975D-57287ACA4CFD

P1476

Q33973884-42077CBF-E96B-426F-8B8C-21D810FAC8B6

P2093

Q33973884-4BD406F0-DA72-45E1-94A4-9F48516FE826

P2860

Q33973884-0D58148C-AD47-4F27-B580-249BE4FCC03B

Q33973884-10FA3F96-BB9E-4760-8DE1-285E8E9C6838

Q33973884-126A037F-B184-4595-A4C6-21479ACAA75D

Q33973884-29C4F009-F434-4C6D-82A7-CD6184B881F3

Q33973884-568544E9-26DB-4CD8-8CF3-EABF099AE1B4

Q33973884-577F3E5C-38EB-4137-A8C9-6CC8820D4F65

Q33973884-5DF9F4BF-E3C1-473A-9CC2-10C7E8DC135B

Q33973884-642DD1D1-1F95-4AF3-9A65-4E4801A31A56

Q33973884-6C9F8D78-52F4-46B4-B543-FBFBCE0A18D7

Q33973884-70A20FC6-8801-4ED7-B1A9-FAFF1515F2AE

P304

Q33973884-E24F03C9-0B73-4734-B94E-2C8697BC5067

P31

Q33973884-7F01F21D-C4BA-4B53-8635-6107115F8887

P356

Q33973884-4E780333-B458-4876-A557-91F831E5CA6E

P407

Q33973884-E638D562-B406-4A35-98F8-0EC8DFF8D4C6

P478

Q33973884-D1103EFE-125D-4C0E-840B-E81692ACCC6D

P50

Q33973884-0863E2C6-9127-488C-8468-BAF2306C397A

P577

Q33973884-D56F6684-5888-4F30-A554-3BED7821FE02

P698

Q33973884-B327CD9B-7985-4080-944D-6812E296346F

P921

Q33973884-F533444A-1DA4-4503-A65A-ACD96CBC1A6A

P932

Q33973884-4366F204-BD7C-4554-828A-45C212A50BB9

P356

P1433

P1476

Golimumab: A novel human anti- ...... litis, and psoriatic arthritis

@en

P2093

Mahboob U Rahman

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense.

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.

P304

159-170

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CE.S6000

http://www.w3.org/2001/XMLSchema#string

P407

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20694072

http://www.w3.org/2001/XMLSchema#string

P921

P932

2899784

http://www.w3.org/2001/XMLSchema#string